

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

STIC-ILL

475637

**From:** Sharareh, Shahnam  
**Sent:** Monday, December 15, 2003 5:06 PM  
**To:** STIC-ILL  
**Subject:** ILL\_Order

please provide a copy of this article. thanks

Hsueh et al., "Platelet-activating factor, tumor necrosis factor, hypoxia and necrotizing enterocolitis", Acta Paediatr. Scand. Suppl. 396:11-17 (1994)

8086673

**Shahnam Sharareh, PharmD**  
**Art Unit 1617**  
**Tel# 306-5400**  
**Mail Box CM1 2B 19**

## Platelet-activating factor, tumor necrosis factor, hypoxia and necrotizing enterocolitis

W Hsueh<sup>1</sup>, MS Caplan<sup>2</sup>, X Sun<sup>1</sup>, X Tan<sup>1</sup>, W MacKendrick<sup>2</sup> and F Gonzalez-Crussi<sup>1</sup>

<sup>1</sup>Department of Pathology<sup>1</sup>, Children's Memorial Hospital, and Department of Pediatrics<sup>2</sup>, Evanston Hospital, Northwestern University Medical School, Chicago, USA

Hsueh W, Caplan MS, Sun X, Tan X, MacKendrick W, Gonzalez-Crussi F. Platelet-activating factor, tumor necrosis factor, hypoxia and necrotizing enterocolitis. *Acta Paediatr* 1994;(suppl 396):11–17. Stockholm. ISSN 0803–5326

The pathogenesis of necrotizing enterocolitis (NEC) is poorly understood. We have established several animal models of NEC by using a combination of various stimuli and stress, including endotoxin, PAF, TNF, and hypoxia. We discuss the mechanism of their actions and the possible roles of these factors in the pathogenesis of human NEC. □ Hypoxia, necrotizing enterocolitis, platelet activating factor, tumor necrosis factor

W Hsueh, Department of Pathology, Children's Memorial Hospital, Chicago, [IL 60614] USA

The etiology and pathogenesis of necrotizing enterocolitis (NEC) are unclear (1). NEC occurs as isolated cases endemically in neonatal nurseries, but sometimes epidemic clusters of cases are seen. The latter occurrence is thought to be caused by infectious agents, although repeated attempts have failed consistently to identify a specific bacteria or virus. Although no definitive etiology has been identified, epidemiological studies point to prematurity (1), infection (2), oral feeding (3), and hypoxia (4) as important risk factors for the development of NEC. We have investigated the role of some of these factors in the pathogenesis of NEC in experimental animals as well as in clinical studies.

### Animal model 1: LPS, PAF and TNF-induced bowel necrosis

Our first model of bowel necrosis was established in rats and mice by injection of endotoxin (lipopolysaccharide, LPS) (5), PAF (platelet-activating factor, paf-acether) (6, 7), tumor necrosis factor- $\alpha$  (TNF, cachectin) (8), or a combination of these agents. The rationale for using these agents was as follows: (a) If the infectious agent which causes NEC is bacterial, resident intestinal flora such as *E. coli* and its toxin product, LPS, would be a highly probable candidate. Previous investigations have shown that oral feeding markedly increases the growth of *E. coli* in the intestinal tract (9), and NEC usually develops following oral feeding. (b) Injection of LPS induces endogenous production of lipid mediators (10, 11) and cytokines (11–13). Among these mediators, PAF and TNF seem to be the most important ones, because administration of PAF (reviewed in refs.

14–16) or TNF (17, 18) to animals mimics symptoms and signs of shock, and pretreatment of the animal with anti-TNF (18) or PAF antagonists (16, 19) prevents LPS-induced shock and increases survival.

PAF is an endogenous phospholipid mediator produced by inflammatory cells, platelets, and endothelial cells (reviewed in refs. 14, 15, 20). In addition, bacteria such as *E. coli* have been reported to be able to synthesize PAF (21, 22). The main source of TNF is monocytes and macrophages (12, 23), although lymphocytes (23, 24) and other tissues (25) have also been shown to produce this cytokine upon stimulation.

Administration of LPS (2–5 mg/kg) alone induces a slow hypotensive response with mild intestinal necrosis in rats (5). The effects of PAF on blood pressure and the intestinal tract are more rapid and dramatic. PAF is probably the most potent agent that induces intestinal injury. In our hands, a dose as small as 1.5  $\mu$ g/kg often causes necrosis of the small intestine of varying degree in the rat in 2 h (26). Since rat platelets are refractory to PAF (6, 27) the development of necrosis is independent of the thromboembolic effect of PAF. The necrosis produced is usually focal (Fig. 1) in the jejunum or ileum, although more frequently in the distal ileum. When a high dose ( $> 3 \mu$ g/kg) is injected into the circulation, the entire small bowel may be affected. Histologically, the necrosis begins at the tip of the villi (6), later extends to the entire mucosa (Fig. 2A), and may become transmural (Fig. 2B) if the dose is sufficiently high. The effects of PAF and LPS are synergistic (Table 1) (6, 7, 28). Furthermore, LPS-induced bowel injury could be blocked by pretreatment with PAF antagonists (5), suggesting that this effect is mediated by endogenous PAF production.




Fig. 1. Development of segmental small bowel necrosis 1 h following injection of PAF ( $2 \mu\text{g/kg}$ , iv) to a Sprague-Dawley rat (approx. 100 g body weight).

Systemic administration of TNF ( $1 \text{ mg/kg}$ ) also induces hypotension and mild intestinal injury in rats (8). When TNF ( $0.5 \text{ mg/kg}$ ) was combined with a small dose of LPS ( $200 \mu\text{g/kg}$ ), profound shock and severe intestinal necrosis developed (8). This synergism is also observed in mice (29, 30). Complement activation probably plays a role in TNF/LPS-induced or PAF-induced bowel injury, since C5 deficient mice are protected from injury (29, 30). Furthermore, injection of TNF/LPS results in endogenous PAF production, which may in turn activate the complement system. This is inferred from our observations that PAF administration causes complement activation in vivo (30), and pretreatment with a PAF receptor antagonist protects mice from TNF/LPS induced shock, complement activation, intestinal injury and death (Table 1) (30).

### Mechanism of PAF-induced bowel injury: roles of leukotrienes, catecholamines, PMNs, oxygen radicals, TNF and endogenous PAF

PAF has a short half-life in the circulation, due to the high plasma and tissue acetylhydrolase activity (31, 32), which rapidly degrades PAF into the biologically inert lyso-PAF. However, the in vivo action of PAF is prolonged. Furthermore, PAF is a vasodilator (33), while at high dose its effect on the mesenteric vascular bed is protracted vasoconstriction (33, 34). One of the explanations is that secondary mediators with sustained splanchnic vasoconstricting action are released after PAF administration. Indeed, we have shown that leukotriene C4 (35) and norepinephrine (36), both having potent splanchnic vasoconstriction effect, are released after PAF injection. Moreover, in vivo administration of leukotriene C/D antagonists (7, 34), or alpha blockers (34), did not reverse shock, but prevented PAF-induced intestinal injury (Table 2). The cytotoxicity effect of PAF is most likely due to reactive oxygen radical formation, since PAF-induced bowel necrosis could be ameliorated by infusion of superoxide dismutase and catalase (37), or allopurinol (37), a xanthine oxidase inhibitor (Table 2).

Another mechanism which may account for the prolonged action of PAF is that PAF not only induces TNF formation in the intestine and liver (38), but also induces its own production in vivo (26). This is demonstrated by the observation that PAF antagonists decreased PAF-induced PAF production in the intestine (Table 2) (5, 26).

The source of secondary mediators is unknown. It is possible that catecholamine is released from the intestinal tissue. Other mediators, such as peptide leukotrienes, oxygen radicals, and endogenous PAF are likely to originate, at least in part, from the resident or infiltrating inflammatory cells. Although it is well established that




Fig. 2. Microscopic appearance of the small intestine from a rat injected with PAF ( $2 \mu\text{g/kg}$ ) showing necrosis of the mucosa (A) and transmural necrosis (B).

Table 1. Effects of PAF, LPS and TNF on systemic blood pressure, hematocrit, and intestinal injury.

Agent (mg/kg)	Species (No. animal)	End B.P.* (mmHg)	Hct	% Gut perf.	% Gross Nec.	Ref.
PAF <sup>a</sup> (.06)	Rat (7)	26 ± 5	71 ± 4	32 ± 6	NR	7
LPS (.6) + PAF <sup>a</sup> (.03)	Rat (11)	44 ± 13	69 ± 5	48 ± 16	NR	7
SRI <sup>c</sup> + LPS (.6) + PAF <sup>a</sup> (.03)	Rat (5)	104 ± 7	49 ± 2	100	0	28
PAF <sup>b</sup> (.015)	Rat (11)	43 ± 10	62 ± 1		60 ± 10	26
WEB <sup>c</sup> (1) - PAF <sup>b</sup> (0.15)	Rat (6)	103 ± 11	50 ± 1		0	26
TNF (1)	Rat (3)	52 ± 14	43 ± 1		17 ± 8	8
TNF (0.5)	Rat (6)	88 ± 8	44 ± 1		0	8
TNF (0.5) + LPS (.2)	Rat (5)	20 ± 5	46 ± 3		35 ± 7	8
SRI <sup>c</sup> + TNF (.5) + LPS (.2)	Rat (3)	62 ± 11	47 ± 2		0	8
PAF <sup>b</sup> (.03)	Mouse (15)	31 ± 3	67 ± 2	10 ± 4 <sup>e</sup>	NR	30
TNF (0.2) + LPS (3)	Mouse (11)	20 <sup>ff</sup>	70 ± 3	9 ± 6	NR	29
SRI <sup>d</sup> + TNF (.2) + LPS (3)	Mouse (6)	59 ± 2		95 ± 2	0	30

\* The experiment usually lasts 2 h.

NR: All animals have gross necrosis. % of intestinal length necrotic not recorded.

PAF<sup>a</sup>: 1-alkyl-2-acetyl-phosphorylcholine used in earlier work may contain mixture of different molecular species of PAF.PAF<sup>b</sup>: Pure 1-hexadecyl-2-acetyl-phosphorylcholine was used in these studies.SRI<sup>c</sup>: SRI 63-119 (3 mg/kg), PAF antagonist (gift from Sandoz Research Institute, E. Hanover, NJ, USA).SRI<sup>d</sup>: SRI 63-441 (5 mg/kg, iv), PAF antagonist (gift from Dr D Handley, Sandoz Research Institute).WEB<sup>e</sup>: WEB 2086, PAF antagonist (gift from Boehringer Ingelheim, Mainz, Germany).<sup>e</sup> Only 3 mice survived at the end of experiment.<sup>ff</sup> Only 1 animal survived at the end of experiment.

macrophages (39), mast cells (40, 41) and endothelial cells (39, 42, 43) are capable of elaborating these mediators, virtually nothing is known about the roles of these cells in the intestine during endotoxin shock or infection. Infiltrating PMNs may play an important role in mediating tissue injury, probably via release of oxygen radicals. This is suggested by the observation that depletion of PMNs by vinblastine prevents PAF-induced or PAF/LPS-induced intestinal injury in rats (44) and mice (30). Another line of evidence is that injection of anti-CD18 (adhesion molecule on PMNs) also prevents the PAF-induced increased endothelial (45) and mucosal (46) permeability. Another potentially important cell in intestinal injury may be Paneth cells. These cells have been shown constitutively to express low levels of TNF (47). Although the mechanism of TNF induction in the bowel is unclear, we have observed increased TNF

gene expression in the Paneth cells, lamina propria eosinophils and infiltrating (but not resident) macrophages in infants with NEC during the acute stage (Fig. 3) (48).

### Animal model 2: role of hypoxia

Hypoxia is one of the major risk factors for NEC, and animal studies in the early 1970s confirmed that both acute asphyxia and prolonged hypoxic exposure resulted in mild mucosal necrosis in animal models (4, 49). However, the pathophysiology of hypoxia-induced bowel injury is not well understood. We found that acute hypoxia (100% N<sub>2</sub>, 2 min) and moderate hypoxia (10% O<sub>2</sub>, 30 min) in weanling rats increased circulating PAF concentrations (13.8 ± 2.9 and 41.1 ± 11.7 ng/ml

Table 2. List of drugs that prevent or ameliorate PAF-induced intestinal necrosis in rats.

Agent	Dose (mg/kg)	Mechanism	Ref.
FPL 55712	5	LTC4/D4 antagonist	7
ICI 198615	10-20	LTC4/D4 antagonist	34
Phenoxybenzamine	20	alpha blocker	34
SOD + catalase	@10*	oxygen radical scavenger	37
Allopurinol	5	xanthine oxidase inhibitor	
WEB 2086	1	PAF antagonist, also blocks endogenous PAF production)	26
PGE1	0.27*	vasodilation, cytoprotect.	34
		inhibits norepinephrine	
Vinblastine	0.75	PMN depletion	30,44

\* Slow iv infusion.




Fig. 3. In situ hybridization study showing a marked increase of TNF mRNA in Paneth cells from a patient with NEC during the acute stage. Light field (A) and dark field (B).

respectively) compared to control animals ( $2.1 \pm 0.8$  ng/ml) (50). Furthermore, pretreatment with PAF antagonist WEB 2086 or SRI 63 441 prevents hypoxia-induced mucosal injury (50). These findings suggest a role of PAF in hypoxia-induced intestinal injury.

However, the above protocol produces only mild mucosal necrosis quite dissimilar from human NEC. In order to further approximate the human disease, we studied the combined effects of LPS and hypoxia on PAF metabolism and intestinal

injury (51). Combining low dose LPS (2 mg/kg, iv) and moderate hypoxia (5%  $O_2$ , 90 min) together, it is possible to induce hypotension, acidosis, mesenteric vasoconstriction, increased intestinal PAF content, and significant bowel necrosis. Furthermore, these morbidities were all attenuated by PAF receptor blockade (Fig. 4). These experiments suggest that hypoxic stress and bacterial products may synergize to cause intestinal injury via PAF production. The cell source of PAF in hypoxic stress is probably endothelium. This is




Fig. 4. Synergistic effect of LPS (2 mg/kg) and hypoxia (5%  $O_2$ , 90 min) on small intestinal hypoperfusion and injury in the rat, and prevention by PAF antagonists. (\*  $p < 0.05$  compared to control). The open bars depict percentage of intestinal perfusion at 3 h using the Evans blue method (7). The filled bars represent percentage of animals with normal histology or minimally abnormal histology in each group. PAF antagonists: WEB 2086 (1 mg/kg, iv) and SRI 63-441 (5 mg/kg, iv).

suggested by our observation that hypoxia (1% O<sub>2</sub>) enhances PAF production by cultured human endothelial cells (52).

### Role of PAF and TNF in human NEC

Despite the substantial evidence supporting the role of PAF and TNF in animal models of bowel necrosis, their role in human NEC remains speculative. To investigate the association between PAF and neonatal NEC, we measured plasma samples from NEC patients and compared them with age-matched control patients with other diseases (53). We found that NEC patients had higher PAF levels ( $18.1 \pm 3.6$  vs  $3.1 \pm 0.9$  ng/ml,  $p < 0.01$ ), higher TNF concentrations ( $136 \pm 75$  vs  $1.5 \pm 0.8$  U/ml,  $p < 0.05$ ), and lower acetylhydrolase (PAF degrading enzyme) activity ( $10.6 \pm 0.7$  vs  $23 \pm 1.4$  nmol/ml/min,  $p < 0.01$ ), than control premature infants. Although these measurements were obtained from severely affected NEC patients, they confirmed an association between circulating PAF, TNF and NEC. In order to investigate the possibility of earlier changes in circulating PAF levels in premature infants at risk for NEC, we prospectively measured plasma PAF and endotoxin in premature infants before and after enteral feeding (a risk factor for NEC), and upon the development of suspected or confirmed NEC (54). We found that significantly more patients had detectable PAF levels after feeding than before feeding (26% vs 7%,  $p < 0.05$ ). Although patients with suspected NEC had similar PAF results compared to controls, infants with proven NEC had markedly elevated PAF levels. These observations confirm that elevated plasma PAF levels are associated with NEC, and suggest that enteral feeding may increase the risk of NEC by increasing circulating PAF.

Since older children and adults do not develop NEC, we hypothesized that PAF metabolism may be different in neonates. We found that serum acetylhydrolase activity was lower for neonates than older children and adult controls ( $8.2 \pm 1.4$  vs  $30 \pm 1.6$  nmol/ml/min,  $p < 0.01$ ), and that the enzyme activity increases linearly with the natural logarithm of age from 0 to 6 weeks when it reaches adult values (55). These results suggest that the decreased ability to degrade circulating PAF may increase the risk of neonates to PAF-related diseases such as NEC.

### Proposed mechanism for the pathogenesis of NEC

Our hypothesis for the pathogenesis of NEC is as

follows: The initial insult could be hypoxia or a mild viral or bacterial infection which results in mild mucosal damage. Following the enteral feeding, the intestinal flora proliferate and may gain entry into the intestinal tissue due to previous mucosal damage and immaturity of the "mucosal barrier", eliciting endogenous production of PAF and TNF. (PAF may also be contributed by the gut bacteria.) If the acetylhydrolase is deficient, PAF may accumulate, synergize with TNF and LPS, reaching the threshold necessary to trigger a cascade of PMN activation, complement activation, and release of oxygen radicals. As a result, focal bowel necrosis develops, which further facilitates bacteria entry, thereby launching a self-perpetuating vicious cycle, resulting in sepsis, shock, and sometimes, death.

**Acknowledgements.**—This work was supported by NIH Grant DK 34574, NIH US Public Health Service Grant RR 05370, and Dee and Moody Foundation Grant 3945.

### References

1. Kliegman RM, Fanaroff AA. Necrotizing enterocolitis. *New Engl J Med* 1984;310:1093–103
2. Kosloske AM, Ulrich JA. A bacteriologic basis for the clinical presentation of necrotizing enterocolitis. 1980; 15:558–64
3. Frantz ID III, L'Heureux P, Engel RR, Hunt CE. Necrotizing enterocolitis. 1975;86:259–63
4. Touloukian RJ, Posch JN, Spencer R. The pathogenesis of ischemic gastroenterocolitis of the neonate: selective gut mucosal ischemia in asphyxiated neonatal piglets. 1972;7:194–205
5. Hsueh W, Gonzalez Crussi F, Arroyave JL. Platelet-activating factor: an endogenous mediator for bowel necrosis in endotoxemia. *FASEB J* 1987;1:403–5
6. Gonzalez Crussi F, Hsueh W. Experimental model of ischemic bowel necrosis. The role of platelet-activating factor and endotoxin. *Am J Pathol* 1983;112:127–35
7. Hsueh W, Gonzalez Crussi F, Arroyave JL. Platelet-activating factor-induced ischemic bowel necrosis. An investigation of secondary mediators in its pathogenesis. *Am J Pathol* 1986;122:231–9
8. Sun XM, Hsueh W. Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor. *J Clin Invest* 1988;81:1328–31
9. Brown EG, Ainbender E, Henley WL, Hodes HL. Etiologic role of bacteria and intestinal function. In: Brown EG, Sweet AY, editors. Neonatal necrotizing enterocolitis. NY: Grune & Stratton, 1980:69–100
10. Feuerstein G, Hallenbeck JM. Prostaglandins, leukotrienes, and platelet-activating factor in shock. *Annu Rev Pharmacol Toxicol* 1987;27:301–13
11. Bone RC. The pathogenesis of sepsis. *Ann Intern Med* 1991;115:457–69
12. Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. *Annu Rev Biochem* 1988;57:505–18
13. Zanetti G, Heumann D, Gerain J, Kohler J, Abbet P, Barras C, et al. Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective

- efficacy of antibodies to tumor necrosis factor- $\alpha$  and to lipopolysaccharide. *J Immunol* 1992;148:1890-7
14. Benveniste J. Paf-acether, an ether phospholipid with biological activity. *Prog Clin Biol Res* 1988;282:73-85
  15. Hanahan DJ. Platelet activating factor: a biologically active phosphoglyceride. *Annu Rev Biochem* 1986;55:483-509
  16. Handley DA. Platelet-activating factor as a mediator of endotoxin-related diseases. In: Handley DA, Saunders RN, Houlihan WJ, Tomesch JC, editors. *Platelet-activating factor in endotoxin and immune diseases*. New York and Basel, Marcel Dekker, Inc., 1990:451-95
  17. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, et al. Shock and tissue injury induced by recombinant human cachectin. *Science* 1986;234:470-4
  18. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT, Kuo GC, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. *Nature* 1987;330:662-4
  19. Toth PD. The biological effects of PAF antagonists on endotoxemia. In: Handley DA, Saunders RN, Houlihan WJ, Tomesch JC, editors. *Platelet-activating factor in endotoxin and immune diseases*. New York and Basel, Marcel Dekker, Inc., 1990:589-608
  20. Snyder F. Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. *Am J Physiol* 1990;259:C697-708
  21. Denizot Y, Dassa E, Kim HY, Bossant MJ, Salem N Jr, Thomas Y, et al. Synthesis of paf-acether from exogenous precursors by the prokaryote *Escherichia coli*. *FEBS Lett* 1989;243:13-16
  22. Denizot Y, Dassa E, Benveniste J, Thomas Y. Paf-acether production by *Escherichia coli*. *Biochem Biophys Res Commun* 1989;161:939-43
  23. Schardene L, Vandenbussche P, Crusiaux A, et al. Differential effects of pentoxifylline on the production of tumour necrosis factor- $\alpha$  and interleukin-6 by monocytes and T Cells. *Immunology* 1992;76:30-4
  24. Goldfeld AE, Strominger JL, Doyle C. Human tumor necrosis factor  $\alpha$  gene regulation in phorbol ester stimulated T and B cell lines. *J Exp Med* 1991;174:73-81
  25. Giroir BP, Johnson JH, Brown T, Allen GL, Beutler B. The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. *J Clin Invest* 1992;90:693-8
  26. Zhang C, Hsueh W, Caplan MS, Kelly A. Platelet activating factor-induced shock and intestinal necrosis in the rat: role of endogenous platelet-activating factor and effect of saline infusion. *Crit Care Med* 1991;19:1067
  27. Sanchez-Crespo M, Alonso F, Inarrea P, Alvarez V, Egido J. Vascular actions of synthetic PAF-acether (a synthetic platelet-activating factor) in the rat: evidence for a platelet independent mechanism. *Immunopharmacol* 1982;4:173-85
  28. Hsueh W, Gonzalez Crussi F, Arroyave JL, Anderson RC, Lee ML, Houlihan WJ. Platelet activating factor-induced ischemic bowel necrosis: the effect of PAF antagonists. *Eur J Pharmacol* 1986;123:79-83
  29. Hsueh W, Sun X, Rioja LN, Gonzalez-Crussi F. The role of the complement system in shock and tissue injury induced by tumour necrosis factor and endotoxin. *Immunology* 1990;70:309-14
  30. Sun X, Hsueh W. Platelet-activating factor produces shock, in vivo complement activation, and tissue injury in mice. *J Immunol* 1991;147:509-14
  31. Stafforini DM, Elstad MR, McIntyre TM, Zimmerman GA, Prescott SM. Human macrophages secrete platelet-activating factor acetylhydrolase. *J Biol Chem* 1990;265:9682-7
  32. Tarbet EB, Stafforini DM, Elstad MR, Zimmerman GA, McIntyre TM, Prescott SM. Liver cells secrete the plasma form of platelet-activating factor acetylhydrolase. *J Biol Chem* 1991;266:16667-73
  33. Siren AL, Feuerstein G. Effects of PAF and BN 52021 on cardiac function and regional blood flow in conscious rats. *Am J Physiol* 1989;257:H25-32
  34. Zhang C, Hsueh W. PAF-induced bowel necrosis. Effects of vasodilators. *Digest Dis Sci* 1991;36:634-40
  35. Hsueh W, Gonzalez Crussi F, Arroyave JL. Release of leukotriene C4 by isolated, perfused rat small intestine in response to platelet-activating factor. *J Clin Invest* 1986;78:108-14
  36. Hsueh W, Gonzalez Crussi F, Arroyave JL. Sequential release of leukotrienes and norepinephrine in rat bowel after platelet-activating factor. A mechanistic study of platelet-activating factor-induced bowel necrosis. *Gastroenterology* 1988;94:1412-8
  37. Cueva JP, Hsueh W. Role of oxygen derived free radicals in platelet activating factor induced bowel necrosis. *Gut* 1988;29:1207-12
  38. Huang L, Tan X, Jiang Y, Reddy J, Hsueh W. PAF and endotoxin induce TNF gene expression in rat intestine and liver. *FASEB J* 1992;6:A1316 (Abstr)
  39. Camussi G, Bussolino F, Salvidio G, Baglioni C. Tumor necrosis factor/cachectin stimulates peritoneal macrophages, polymorphonuclear neutrophils, and vascular endothelial cells to synthesize and release platelet-activating factor. *J Exp Med* 1987;166:1390-404
  40. Perdue MH, Ramage JK, Burget D, Marshall J, Masson S. Intestinal mucosal injury is associated with mast cell activation and leukotriene generation during *Nippostrongylus*-induced inflammation in the rat. *Digest Dis Sci* 1989;34:724-31
  41. Ninio E, Joly F, Hieblot C, Bessou G, Mencia Huerta JM, Benveniste J. Biosynthesis of paf-acether. IX. Role for a phosphorylation-dependent activation of acetyltransferase in antigen-stimulated mouse mast cells. *J Immunol* 1987;139:154-60
  42. Zimmerman GA, Whatley RE, McIntyre TM, Prescott SM. Production of platelet-activating factor, a biologically active lipid, by vascular endothelial cells. *Am Rev Respir Dis* 1987;136:204-7
  43. Feinmark SJ. The role of the endothelial cell in leukotriene biosynthesis. *Am Rev Respir Dis* 1992;146:S51-5
  44. Mosemiche C, Caplan M, Hsueh W, Sun XM, Kelly A. Experimental necrotizing enterocolitis. *J Pediatr Surg* 1991;26:1047-9
  45. Kubes P, Suzuki M, Granger DN. Platelet-activating factor-induced microvascular dysfunction: role of adherent leukocytes. *Am J Physiol* 1990;258:G158-63
  46. Kubes P, Arfors KE, Granger DN. Platelet-activating factor-induced mucosal dysfunction: role of oxidants and granulocytes. *Am J Physiol* 1991;260:G965-71
  47. Keshav S, Lawson L, Chung LP, Stein M, Perry VH, Gordon S. Tumor necrosis factor mRNA localized to Paneth cells of normal murine intestinal epithelium by in situ hybridization. *J Exp Med* 1990;171:327-32
  48. Tan XD, Hsueh W, Gonzalez-Crussi F. Cellular localization of TNF- $\alpha$  transcripts in normal bowel and in necrotizing enterocolitis. TNF gene expression in Paneth cells, intestinal eosinophils and macrophages. *Am J Pathol* 1993;142:1858-65
  49. Hansbrough F, Priebe CJ Jr, Falterman KW, Bornside GH, Welsh RA. Pathogenesis of early necrotizing enterocolitis in the hypoxic neonatal dog. *Am J Surg* 1983;145:169-75
  50. Caplan MS, Sun XM, Hsueh W. Hypoxia causes ischemic bowel necrosis in rats: the role of platelet-activating factor (PAF-acether). *Gastroenterology* 1990;99:979-86
  51. Caplan MS, Kelly A, Hsueh W. Endotoxin and hypoxia-induced intestinal necrosis: the role of platelet activating factor. *Ped Res* 1992;31:428-34
  52. Caplan MS, Alder L, Kelly A, Hsueh W. Hypoxia increases ionophore-induced PAF production and release from human umbilical vein endothelial cells. *Biochim Biophys Acta* 1992;1128:205-10



53. Caplan MS, Sun XM, Hsueh W, Hageman JR. Role of platelet activating factor and tumor necrosis factor-alpha in neonatal necrotizing enterocolitis. *J Pediatr* 1990;116:960-4
54. MacKendrick W, Hill N, Hsueh W, Caplan M. Increase in plasma platelet activating factor levels in enterally fed preterm infants. *Biol Neonate* 1993;64:89-95
55. Caplan M, Hsueh W, Kelly A, Donovan M. Serum PAF acetylhydrolase increases during neonatal maturation. *Prostaglandins* 1990;39:705-14